SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-194057
Filing Date
2023-07-26
Accepted
2023-07-26 07:42:31
Documents
13
Period of Report
2023-07-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d480656d8k.htm   iXBRL 8-K 50563
2 EX-99.1 d480656dex991.htm EX-99.1 27726
  Complete submission text file 0001193125-23-194057.txt   218897

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inzy-20230726.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20230726_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20230726_pre.xml EX-101.PRE 11707
7 EXTRACTED XBRL INSTANCE DOCUMENT d480656d8k_htm.xml XML 3463
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 231110057
SIC: 2834 Pharmaceutical Preparations